EU and US could reach trade deal this weekend - Reuters
SHANGHAI - Ondine Biomedical Inc. (AIM:OBI), a pioneer in photodisinfection technology, has announced significant progress in combating multidrug-resistant pathogens at the 19th World Congress of the International Photodynamic Association held this week. The company introduced an innovative robotic tool that employs artificial intelligence to determine the most effective combinations of antimicrobial treatments for eradicating various pathogens.
The research presented by Ondine scientist Micah Chavez showcases a novel high-throughput robotic assay that uses an optical checkerboard technique to perform multiple microbiological tests simultaneously. These tests are designed to meet the Clinical and Laboratory Standards Institute and American Society for Microbiology guidelines. The tool’s AI algorithms help to identify optimal pairings of photodisinfection with traditional antimicrobials for both topical and systemic treatment of drug-resistant infections.
Dr. Nicolas Loebel, President and CTO of Ondine, highlighted the urgency of developing new strategies to combat the growing threat of drug-resistant pathogens, which pose significant health risks and economic burdens worldwide. According to Dr. Loebel, the company’s findings indicate that photodisinfection can substantially increase the effectiveness of antibiotics such as vancomycin, ciprofloxacin, and tetracycline, as well as antiseptics like benzalkonium chloride and chlorhexidine.
This advancement suggests a potential dual-mode therapy, which could revolutionize infection prevention strategies by providing a powerful topical treatment with photodisinfection while simultaneously enhancing the local efficacy of systemic oral and injectable antimicrobials.
Ondine’s technology is the foundation of Steriwave®, its flagship product aimed at preventing healthcare-associated infections by eliminating pathogens in the nasal cavity. Steriwave is currently in use in leading healthcare institutions in Canada and the UK, including the CanHealth Network and the NHS. Additionally, a pivotal clinical trial is in progress to support an FDA regulatory submission in the United States.
This news, based on a press release statement from Ondine Biomedical, sheds light on potential advancements in the field of antimicrobial therapies and the ongoing battle against multidrug-resistant infections.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.